Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 806 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR New drug available for rare thyroid cancer on NHS in England October 1, 2021 Welcome to our new committee chairs November 22, 2022 FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma October 27, 2025 FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or... December 2, 2021 Load more HOT NEWS Treatment Benefit with Quizartinib, a Potent and Specific FLT3 Inhibitor for... Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell... A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year... 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free.
